Tag: marijuana

Organ Donations From Marijuana Users Pose No Significant Infectious Risks, Study Finds

A new federally funded study examining the possible risks of organ donation by marijuana users found no indication that recent cannabis use increases the likelihood of significant side effects in the year immediately after a transplant—even as many healthcare providers continue to restrict transplants to cannabis consumers.

Findings of the research, which looked at rates of infections, transplant failures and deaths among recipients, “suggest that organs from donors with a history of recent marijuana use do not pose significant infectious risks in the early posttransplant period.”

“Despite concern that donor exposure to marijuana increases the risk of fungal infection in recipients, our study found that a donor history of marijuana use did not increase (1) the likelihood of donor culture positivity (including respiratory cultures), or (2) the risk of early recipient bacterial or fungal infection, graft failure, or death posttransplant,” authors wrote. “Even when evaluating only lung recipients, there remained no association between donor marijuana use and the risk of posttransplant infection.”

As more states have legalized marijuana, reported rates of use among adults have also risen, notes the new study, published late last month in the American Journal of Transplantation. “It is likely that a growing proportion of deceased organ donors have a history of marijuana use, as well,” it says, “though this metric has not been specifically reported.”

Keep reading

Smart Approaches to Marijuana Exec Attacks ‘Fake’ Cannabis Research on Fox

Anti-cannabis political organization Smart Approaches to Marijuana (SAM) was represented on Fox News primetime to expose what they believe to be fake research promoted in greed by the cannabis industry. SAM is a political organization opposed to cannabis legalization and commercialization, specifically pushing for penalties for cannabis use.

Executive Vice President of SAM Luke Niforatos joined Laura Ingraham on The Ingraham Angle to discuss how “Big Cannabis” is funding UCLA, Harvard, and MIT studies on the efficacy of cannabis for medical purposes.

“The mainstreaming of pot has come at the same time the drug has increased exponentially in its potency, its THC levels,” warned Ingraham, linking it to “violent behavior.” Ingraham frequently explores the dangers of pot and blamed “pot psychosis” due to widespread legalization for the rise in mass shooting incidents. 

Niforatos then delivered a new mixed bag of reefer madness and hysteria: “Big marijuana is terrified right now, because there are now volumes of research telling us that this new super-charged marijuana that the industry is pumping out is causing psychosis, schizophrenia,” Niforatos said. “We’re seeing addiction rates go up. They’re targeting our kids. All kinds of car crashes on the roads! So all of this is coming out of the research.”

Keep reading

Marijuana Can Help Increase Orgasm Frequency And Satisfaction For Women, Study Finds

As at least four U.S. states weigh whether to add female orgasmic disorder (FOD) as a qualifying condition for medical marijuana, a newly published journal article by one of the organizers of that effort further reinforces the potential benefits offered by cannabis, including increased orgasm frequency, improved satisfaction and greater ease achieving orgasm.

Published this month in The Journal of Sexual Medicine, the report is the product of a 2022 observational study by authors Suzanne Mulvehill, a clinical sexologist, and Jordan Tishler, a doctor at the Association of Cannabinoid Specialists and the company inhaleMD. While decades of sexuality research support the use of marijuana for sexual difficulties, the authors said, theirs is “the first study to look at FOD specifically, demonstrating significant benefit.”

The survey of 387 participants found that more than half (52 percent) said they experienced orgasm difficulty.

“Among respondents reporting orgasm difficulty, cannabis use before partnered sex increased orgasm frequency (72.8%), improved orgasm satisfaction (67%) or made orgasm easier (71%),” the study found.

Keep reading

Marijuana Consumers Have ‘Significantly Decreased Odds’ Of Cognitive Decline, Study Finds

Marijuana use is associated with lower odds of subjective cognitive decline (SCD), according to a new study, with people who consume cannabis for recreational or medical purposes reporting less confusion and memory loss compared to non-users.

The study—which showed that recreational cannabis use is “significantly” linked to lower SCD—is especially notable given that past research has connected subjective decline to the development of dementia later in life.

The results, which were published in the journal Current Alzheimer Research this month, indicate that THC’s impacts on cognitive function may be more complicated than popularly assumed.

“Compared to non-users,” the study says, “non-medical cannabis use was significantly associated with 96% decreased odds of SCD.”

People who reported using marijuana for medical purposes, or for both medical and recreational purposes, also showed “decreased odds of SCD, although not significant,” the study found.

To be sure, a number of earlier studies have indicated negative associations between heavy cannabis use and mental performance. Authors of the new study, out of SUNY Upstate Medical University in Syracuse, pointed to past results linking long-term or frequent cannabis use to compromised verbal recall performance, worsened cognitive function and subjective memory complaints, for example.

“However, the cognitive implications of cannabis are not only determined by the frequency of cannabis consumption,” they wrote, noting that other factors—including product formulation, method of administration and reason for use—may also “impact the cognitive effects associated with cannabis use.”

“Our study addresses these knowledge gaps by comprehensively examining how reason, frequency, and method of cannabis use are associated with SCD among U.S. middle-aged and older adults,” their report says.

Keep reading

Equity Advocates ‘Correct The Record’ On Biden’s Marijuana Actions And Shortcomings Of Anticipated Schedule III Move

A coalition of drug policy reform advocates is seeking to “correct the record” on the Biden administration’s marijuana policy achievements, calling attention to unfulfilled campaign promises to Black and brown communities on cannabis reform and criticizing the limitations of incremental rescheduling.

During a virtual press briefing organized by the Drug Policy Alliance (DPA) on Wednesday, representatives of multiple equity-focused cannabis organizations pushed back on the administration’s modest reform steps, contending that anything short of ending federal marijuana criminalization would represent a disservice to the communities most impacted under prohibition.

Maritza Perez Medina, director of federal affairs at DPA, stressed during the briefing that moving marijuana to Schedule III under the Controlled Substances Act (CSA), as the U.S. Department of Health and Human Services (HHS) has recommended to the Drug Enforcement Administration (DEA), is “something that our communities cannot accept.”

“As long as marijuana remains anywhere on the CSA, the harms of federal marijuana criminalization will continue,” she said.

Cat Packer, vice chair of the Cannabis Regulators of Color Coalition (CRCC) and director of drug markets and legal regulation at DPA, said the Biden administration’s commentary around its marijuana policy achievements “illustrates the need for Black and brown communities to correct the record of what promises have been made to our communities and whether any promises have been kept.”

President Joe Biden campaigned on a pledge to federally decriminalize marijuana—and he’s said repeatedly that nobody should be incarcerated over cannabis. But despite granting pardons for people who’ve committed certain federal marijuana possession offenses and directing a scheduling review, those broader promises have not yet been achieved.

“Rescheduling marijuana to Schedule III—the outcome that is anticipated to result from the Biden administration’s actions—would continue the very criminalization that Biden said that he would end and is the very type of incrementalism that [Vice President Kamala Harris] criticized in 2020,” Packer said. “Where’s the accountability to Black and brown communities to whom these reforms were promised?”

Keep reading

FDA Official Says Agency Is ‘Actively’ Exploring CBD Regulations As It Continues To Monitor Kratom

The Food and Drug Administration (FDA) is “actively” exploring a potential regulatory framework for CBD, with plans to prioritize the issue in the next year, a top official says. Meanwhile, the agency is also investigating issues related to kratom.

FDA Deputy Commissioner for Policy, Legislation, and International Affairs Kimberlee Trzeciak discussed the agency’s cannabis and kratom interests during a webinar hosted by the Alliance for a Strong FDA this month.

Asked about issues that are “top of mind” for the agency in 2024 and where officials hope to engage with Congress, Trzeciak said that later this year or next year FDA wants to address setting up “an appropriate regulatory framework for CBD.”

Later in the conversation, the FDA official was asked specifically about how the agency is “prioritizing” its work on cannabis and kratom regulations, and she said officials are taking a number of factors into consideration as they work to address the substances.

“In almost every neighborhood you go to, you can see stores on the corners that are marketing CBD and kratom and others,” she said. “And one of the things that we have been thinking through here at FDA, using CBD as an example, is what does the regulatory framework for those products look like?”

“Based on what we know about CBD in particular, we do not think that those products would be able to meet the safety standards that we have in place for foods and dietary supplements today,” she said, referencing the agency’s position after it declined to enact regulations for the non-intoxicating cannabinoid that was legalized under the 2018 Farm Bill.

“What can we do in terms of regulatory tools to ensure that this product is going to be marketed that consumers are clearly aware of what the product is, what is in it and making sure that we have basic information about the marketplace?” Trzeciak said. “I like to think of it as the common regulatory tool that we have across the other products that we regulate.”

She added that FDA wants to “work with Congress on this effort,” including possible rulemaking around CBD product labeling and packaging.

“For example, how can we ensure that the agency knows if there are adverse events that are being reported, so we can identify those trends, making sure that the product is being manufactured or produced in a way that’s safe and quality?” she said.

Kratom reform advocates say the deputy commissioner’s comments represent a “shift” in the agency’s policy perspective on the issue. Historically, FDA hasn’t engaged in the kratom debate as actively as other agencies such as the National Institute on Drug Abuse (NIDA).

Keep reading

New Idaho Bill Would Apply $420 Mandatory Minimum Fine For Marijuana Possession

Anyone convicted of possessing less than three ounces of marijuana in Idaho would receive a mandatory minimum fine of $420 if a new bill introduced in the Idaho Legislature becomes law.

House Bill 606 is Rep. Bruce Skaug’s second attempt to pass a bill creating a mandatory minimum fine for possession of less than three ounces of marijuana, after House Bill 559 was introduced on February 13.

On Tuesday, Skaug, R-Nampa, told members of the House State Affairs Committee that House Bill 606 replaces House Bill 559 and makes a technical correction. The difference is the newest bill adds language that basically says any other penalties specified in state law can also be applied, in addition to the $420 fine.

If passed into law, the new bill would amend the existing penalties in Idaho law for manufacturing, delivery or possession of controlled substances. Idaho law already specifies that anyone possessing more than three ounces of marijuana can be punished with a prison sentence of up to five years and a fine of up to $10,000, or both. The new bill simply adds a fine of not less than $420 for possession of less than three ounces of marijuana. State law describes marijuana as “all parts of the plants of the genus cannabis, including the extract or any preparation of cannabis which contains tetrahydrocannabinol.”

The $420 fine is a known reference to slang for getting high on marijuana. During Tuesday’s short introductory hearing, Skaug also dropped several marijuana-related puns when he told committee he “smoked out” the problem in his last bill and ran the changes by his assistant, “Mary Jane.”

Other than Wyoming, Idaho’s neighboring states have legalized medical or recreational marijuana. Utah allows for the possession and use of medical marijuana for qualified patients who have a medical cannabis card. Washington, Oregon, Montana and Nevada allow recreational marijuana.

Keep reading

Analysis: Cannabis Products Provide Sustained Improvements In Sleep Quality For Patients With Insomnia

Insomnia patients who consume cannabis products report sustained improvements in their sleep quality, according to data published in the journal Brain & Behavior. 

British investigators assessed the safety and efficacy of plant-derived cannabis products (either oils, flower, or a combination of both) in over 60 patients enrolled in the UK Medical Cannabis Registry. Cohort participants possessed a doctor’s authorization to access cannabis products. (Since 2018, specialists have been permitted to prescribe cannabis-based medicinal products to patients unresponsive to conventional medications.) Authors assessed the efficacy of cannabis at one, three, and six months.

Researchers reported that cannabis products were “well tolerated” and that they were associated with better sleep, reduced anxiety, and greater quality of life. 

They concluded: “More than 40 percent of participants who completed each PROM [patient-reported outcome measure] round reported clinically significant improvement in their sleep quality at each time period. These results show that initiation of CBMP [cannabis-based medicinal products] therapy was associated with improvements in those patients who had previously failed to respond to currently licensed treatments for insomnia.”

Keep reading

North Carolina Judge Bans People With The ‘Odor Of Marijuana’ From Entering Courts

Anyone who “has the odor of marijuana” will be banned from entering the North Carolina Superior Courts of Robeson County from here on out under an order signed by a judge on Wednesday.

The order says that smelling like cannabis will be grounds for removal from the courthouse, and the sheriff will be directed to “ask you to leave and come back without the odor owns [sic] your persons.”

A “findings of fact” section states that “the Robeson County Courthouse is a government facility open to the people for the purpose of conduction official business for the State of North Carolina.”

“The public is free to enter the courthouse during normal hours of operation to conduct business and the courthouse should be readily and reasonably accessible to the public in such a fashion that the safety and health of those entering the courthouse to conduct business, as well as those who work in the courthouse on a regular basis, are not threatened or impaired,” the order from Senior Resident Superior Court Judge James Gregory Bell says.

Keep reading

Georgia $150M class action lawsuit accuses STIIIZY, Cookies, others of selling marijuana as hemp

A federal racketeering lawsuit filed in Georgia last week alleges that California cannabis brand leaders STIIIZY and Cookies – along with 12 co-conspirators – illegally sold marijuana products that had been intentionally mislabeled as federally-legal delta-8 hemp goods, and asks for a minimum of $150 million in damages.

The class action suit, filed Feb. 6 in U.S. District Court in the northern district of Georgia, claims that resident Hannah Ledbetter was misled by the defendants into purchasing the federally illegal marijuana products that had been sold as federally legal hemp goods that included 0.3% delta-8 THC or less, which is the federal threshold for legal hemp products.

“Defendants have conspired to import, manufacture, distribute, and possess illegal (delta-8) THC vape pens that are marijuana” and not hemp under federal law, the suit charges. “This scheme could only be accomplished through a pattern of racketeering activity.”

The suit asserts that Ledbetter carefully inspected the product labels prior to purchase “because she did not want to break the law.”

Rather, the suit claims, the products that Ledbetter ultimately bought – at multiple retail chains that do business in Georgia – were found to have delta-9 THC “far above what is allowed by law,” according to third-party testing results.

STIIIZY IP LLC, Cookies Creative Consulting & Promotions, and their partners “have facilitated the manufacturing, distribution, and/or sale of illegal marijuana to thousands of people over the course of the last four years,” the suit charges

Keep reading